- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Celebrating Innovation: Prix Galien Photo Gallery
Pharmaceutical Executive
Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.
The Prix Galien Awards were established more than 30 years ago in France to honor research innovation within the pharmaceutical industry. Since their creation, the awards have expanded to other countries around the globe. This year marked the first time the Prix Galien Awards honored American innovation. The black-tie event—held on Sept. 25, 2007, at New York City's swank Cipriani—was truly a star-studded affair, presided over by television personality Charlie Rose and featuring a special appearance by author and Nobel Peace Prize laureate Elie Wiesel. Medals were awarded by an esteemed panel of judges, including the six Nobel laureates in attendance. Pfizer's Chantix and Merck's Januvia took home awards for best pharmaceutical product, and Abbott Labs' Humira and Merck's Gardasil won in the biotech class—but a good time was had by all.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
